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ABSTRACT
Background Patients with encephalitis associated with
antibodies against N-methyl-D-aspartate-receptor
antibody (NMDAR-ab) encephalitis frequently show
psychotic symptoms, amnesia, seizures and movement
disorders. While brain MRI in NMDAR-ab encephalitis is
often normal, abnormalities of cerebral glucose
metabolism have been demonstrated by positron
emission tomography (PET) with 18F-fluorodeoxyglucose
(FDG) in a few usually isolated case reports. However,
a common pattern of FDG-PET abnormalities has not
been reported.
Methods The authors retrospectively identified six
patients with NMDAR-ab encephalitis in two large
German centres who underwent at least one whole-body
FDG-PET for tumour screening between January 2007
and July 2010. They analysed the pattern of cerebral
uptake derived from whole-body PET data for
characteristic changes of glucose metabolism compared
with controls, and the changes of this pattern during the
course of the disease.
Results Groupwise analysis revealed that patients with
NMDAR-ab encephalitis showed relative frontal and
temporal glucose hypermetabolism associated with
occipital hypometabolism. Cross-sectional analysis of the
group demonstrated that the extent of these changes is
positively associated with clinical disease severity.
Longitudinal analysis of two cases showed normalisation
of the pattern of cerebral glucose metabolism with
recovery.
Conclusions A characteristic change in cerebral glucose
metabolism during NMDAR-ab encephalitis is an
increased frontotemporal-to-occipital gradient. This
pattern correlates with disease severity. Similar changes
have been observed in psychosis induced by NMDAR
antagonists. Thus, this pattern might be a consequence
of impaired NMDAR function.
BACKGROUND
A recently described encephalitis subtype, mostly
in young women and children, and associated with
good recovery and response to immunotherapy, is
characterised by antibodies (abs) directed against
the NR1-subunit of the N-methyl-D-aspartate
receptor (NMDAR).1 The incidence is unknown;
1% of young patients in a German intensive care
unit2 and 4% of all encephalitis syndromes in
a large British multicentre study3 were affected.
Patients often present with severe memory loss,
epileptic seizures, psychiatric disturbances, espe-
cially psychosis, movement disorders, hypo-
ventilation and catatonic states. Cerebral MRI
shows no abnormalities in half the patients, and
only unspeciﬁc changes in the grey and white
matter in the remaining patients.1 In some
patients, ovarian teratomas, and seldom other
tumours, are detected as the underlying cause of
the disease.1
Single-case reports have shown temporal and
extratemporal glucose hypermetabolisms in 18F-
ﬂuoro-2-deoxy-D-glucose (FDG) positron emission
tomography (PET).4e9 However, a metabolic
pattern typical for NMDAR-ab encephalitis has not
been described.
In order to detect underlying gonadal or extra-
gonadal neoplasms, whole-body FDG-PET is
frequently performed in patients with NMDAR-ab
encephalitis. The objective of this study was to
determine if there is a frequent or characteristic
pattern of cerebral glucose metabolism in NMDAR-
ab encephalitis by systematic analysis of brain FDG
uptake from whole-body FDG-PETs in a cohort of
retrospectively identiﬁed patients with this
syndrome in order to improve diagnostic accuracy
and gather insights into the pathophysiology of the
disease.
METHODS
Patient selection
Patients with NMDAR-ab encephalitis were retro-
spectively identiﬁed between 1 January 2007 and 31
July 2010 in the Department of Neurology,
University Medical Center Hamburg-Eppendorf, or
University Medical Center Regensburg. Diagnostic
criteria where two or more acute or subacute
evolved clinical symptoms (memory disturbances,
psychiatric symptoms, epileptic seizures, reduced
level of consciousness, movement disorder) plus
either cerebrospinal ﬂuid pleocytosis or oligoclonal
immunoglobulin G (IgG) plus IgG NMDAR-ab in
serum, or cerebrospinal ﬂuid of at least 1:10.
NMDAR-ab detection was performed by indirect
immunoﬂuorescence with HEK293 cells recombi-
nantly expressing NR1 NMDAR (Mosaik Biochip,
Euroimmun, Germany).10 Data extracted from the
ﬁles included basic demographics, onset of symp-
toms, initial hospitalisation, clinical presentation,
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treatment, imaging studies and disability according to the
modiﬁed Rankin Scale (mRS).11 Of 10 patients diagnosed with
NMDAR-ab encephalitis between 2007 and 2010, 6 patients (4
women and 2 men, mean 21 years, range 19e39 years) had been
examined by whole-body FDG-PET, two of whom had a follow-
up whole-body FDG-PET. In all scans, brain FDG uptake could
be extracted from the whole-body FDG-PET. In all cases, mRS
was documented in patient ﬁles upon admission and at last
follow-up visit. All patients were suffering from moderate to
severe disease (median mRS 4.5, range 3e5). Further demo-
graphic data is provided in the online supplementary table 1. All
patients had detectable serum NMDAR-abs and presented with
prominent psychiatric features. In all patients included, cerebral
MRI with axial FLAIR, diffusion-weighted images, native T1
and gadolinium (gd)-enhanced T1 images were available within
2 weeks prior to FDG-PET. All patients underwent repeated
neuropsychological testing (median 3 times) during the course of
disease (median 8 weeks after onset). Recovery of cognitive
functions correlated well with decrease of mRS (not shown).
FDG-PET
Whole-body FDG PET/CT for detection of neoplasms had been
performed with a PET/CTsystem Gemini GXL 10 (Royal Philips
Electronics, The Netherlands) or Biograph 16 (Siemens,
Germany). Imaging started with a non-enhanced, low-dose CT
of the whole body about 60 min after intravenous injection of
300e400MBq FDG. Whole-body PET was performed immedi-
ately after CT. Transversal PET slices were reconstructed with
CT-based attenuation correction using an iterative algorithm.
Spatial resolution was 9 mm full-width-at-half-maximum
(FWHM). For further processing, the attenuation-corrected PET
images of the brain were separated from the whole-body scan
using the PMOD software package V.3.204 (PMOD Technolo-
gies, Zurich, Switzerland).
Voxel-based statistical testing
The brain image was stereotactically normalised using the
‘Normalize-Tool’ of the Statistical Parametric Mapping software
package (SPM2, default parameter settings).12 The stereotacti-
cally normalised image was smoothed with an isotropic 3D
Gaussian kernel with 14 mm FWHM. The confounding effect of
global FDG uptake was removed by scaling voxel intensities in
the smoothed image to the average voxel intensity over the
whole brain (SPM proportional scaling).
For single-subject analysis, the scaled FDG-PET brain image of
the patient was compared voxel-by-voxel with corresponding
images of a control group described below (one-sided two
sample t tests for hypo- and hypermetabolism; a ¼0.001
uncorrected for multiple comparisons, no non-sphericity
correction). Only effects in clusters of at least 1 ml were
considered. Mean FDG uptake in the frontal, temporal and
occipital lobe was calculated by using volumes of interest
predeﬁned in the TD Lobes atlas of the WFU Pick Atlas Toolbox
V.2.4).13 The ratio of frontal-to-occipital and temporal-to-
occipital FDG uptake was tested for correlation with the mRS
using the Spearman test, and for groupwise comparison
(mRS>0 to controls) by unpaired two-tailed t test.
For detection of changes in the follow-up PETcompared with
the baseline PET, voxel-based subtraction analysis was
performed as previously described.14 Images were smoothed
with an isotropic 3D Gaussian kernel with 30 mm FWHM prior
to subtraction analysis. Effects larger than 2 SDs were consid-
ered statistically signiﬁcant.
For group analysis, scaled FDG uptake was compared voxel-
by-voxel between the group of patients and the control group.
One patient (patient #6) was excluded from the group analysis,
because of the limited ﬁeld of view (online supplementary ﬁgure
1). Statistical signiﬁcance was deﬁned via a false discovery rate
of 0.05.15
The control group consisted of 24 patients who underwent
whole-body FDG-PET, including the brain, because of non-CNS
oncological indications: gonadal tumour (n¼5), bronchial (n¼3),
thyroid (n¼1), oesophageal (n¼1), pancreatic (n¼1) or mamma
(n¼1) carcinoma, non-Hodgkin’s (n¼4) or Hodgkin’s (n¼2)
lymphoma, melanoma (n¼3), osteosarcoma (n¼1), rhabdo-
myosarcoma (n¼1) or granulosa cell tumour (n¼1) (age
38616 years, 14 women; age not signiﬁcantly different from the
group with NMDAR-ab encephalitis, p¼0.10, two-sided t test).
Exclusion criteria were known psychiatric or neurological
disorder, psychotropic medication at the time of the PET, and
abnormal PET ﬁndings in the brain based on visual evaluation of
the PET images by an experienced reader. The control subjects
had been tested by SPM2 statistical analysis using the leave-one-
out strategy. Subjects with any signiﬁcant cluster of either hypo
or hypermetabolism (a ¼0.05, corrected for multiple compari-
sons) had been excluded. PET acquisition and image recon-
struction protocol was the same in the group of NMDA-ab
encephalitis patients and the control group.
RESULTS
Patient characteristics
Cerebral MRI was normal in four patients (#1,4e6). Patient #2
had multiple small subcortical T2-hyperintensities without Gd
enhancement, and patient #3 had three periventricular T2-
hyperintense and slightly Gd-enhancing lesions without corre-
sponding FDG-PET abnormalities.
Median time between onset of the disease and ﬁrst FDG-PET
was 10 weeks (range 10 weeks prior to 30 weeks after disease
onset). Patients #2e6 were at the peak of the disease. In one
male patient (#1), PETwas performed 10 weeks prior to onset of
symptoms to screen for extragonadal manifestations of a differ-
entiated teratoma (left testis pT2N0M0, diagnosis 5 months
before, no tumour on right-sided testis biopsy). No tumour was
found in the other patients. Two patients had epileptic seizures
prior to PET imaging (1, 4 weeks) and were successfully treated
with anticonvulsants at the time of FDG-PET (patients #5 and
#6). In the other patients, no seizures occurred before PET
imaging.
First-line treatment was with steroids (median 1 week, range
4 weeks prior to 15 weeks after ﬁrst PET). Five patients were
additionally treated with plasmapheresis, two received intrave-
nous Igs, four were eventually treated with rituximab and one
with cyclophosphamide. Outcome at last follow-up was gener-
ally good (two patients each mRS 0, mRS 1, mRS 2), and all
patients had shown improvement of varying degrees.
Individual regional abnormalities of brain glucose metabolism
Voxel-based statistical analysis of the individual cerebral FDG-PET
showed abnormalities in each of the six patients (table 1, repre-
sentative images in ﬁgure 1, all images available in online supple-
mentary ﬁgure 1). While some patients displayed only restricted
temporomesial or frontal increased uptake (ﬁgure 1, patient #1
and #2), in others widespread frontotemporal hyper- and biocci-
pital hypometabolism were observed (ﬁgure 1, patient #4 and
#6). In patients with pronounced changes (ﬁgure 1, patient #4
and #6), also cerebellar cortical hypermetabolism was noticed.
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One male patient (#1) did not have any symptoms at the
time of FDG-PET (mRS 0), but was severely affected (mRS 5)
10 weeks later. At that time, no additional FDG-PET was
performed. NMDAR positivity was diagnosed after recovery.
Thus, this image represents a presymptomatic situation in
which already slight temporomesial hypermetabolism was
detected (ﬁgure 1, left panel). Of note, this was the only patient
in whom FDG-PET only revealed mesiotemporal hypermetabo-
lism, but neither frontal hyper- nor occipital hypometabolism.
Taken together, all patients with NMDAR-ab encephalitis
with the exception of patient #3 showed temporal glucose
hypermetabolism. Moreover, all but the presymptomatic patient
(#1) showed either increased frontal or decreased occipital
glucose metabolism.
Recovery is associated with decreased frontotemporal and
increased occipital glucose metabolism
In two patients (#3 and #5, initial mRS 3 and 5, respectively),
initial brain glucose metabolism during active disease could be
compared with PET images after recovery (116 and 128 weeks
after onset of disease, both mRS 1). In both cases, individual
subtraction analysis revealed an almost identical pattern of
changes in glucose metabolism upon recovery with decreased
frontal and increased occipital metabolism (ﬁgure 2A). Of note,
in both cases, the changes were much more widespread than
expected by single-subject analysis for abnormal glucose
metabolism compared with the control group (online supple-
mentary ﬁgure 1). In summary, upon clinical recovery the intra-
individual analysis showed a reverse pattern compared with the
frontal and temporal hyper- and occipital hypometabolism
observed in the single-subject analysis.
Group analysis confirms temporal and frontal hypermetabolism
in association with occipital hypometabolism as a general
pattern of abnormal brain glucose metabolism in NMDAR-ab
encephalitis
FDG-PETof the presymptomatic patient and the remaining four
patients with clinically active disease and full ﬁeld-of-view was
compared with the control group (online supplementary ﬁgure
1, patients #1e5). Statistically signiﬁcant hypermetabolism was
conﬁrmed in both temporomesial areas, in the right prefrontal
cortex and frontobasal areas. Signiﬁcant and widespread hypo-
metabolism was conﬁrmed in bioccipital areas extending to left-
sided parietal areas (ﬁgure 2B).
The fronto- and temporo-to-occipital gradient of cerebral FDG
uptake correlates with disease severity and normalises after
recovery
The pattern of individual abnormalities in FDG uptake, or the
changes upon recovery, indicated that relative frontal and
temporal hyper and occipital hypometabolism were character-
istic changes in FDG-PET imaging in NMDAR-ab encephalitis in
four of ﬁve patients with active disease (patients #3e6). Group
analysis conﬁrmed this pattern. However, cerebral FDG uptake
in our analysis of regional hyper- and hypometabolism was
normalised to individual whole-brain uptake, and does not
represent absolute, but relative changes. Thus, both observations
the relative frontal and temporal hypermetabolism and the
relative occipital hypometabolism might result from the same
mechanism, an increased gradient of frontal and temporal areas
to the occipital lobes. We tested this hypothesis by calculating
an individual fronto-to-occipital FDG uptake ratio (F/O-R) and
temporo-to-occipital FDG uptake ratio (T/O-R) on the basis of
relative FDG uptake in anatomically deﬁned temporal, frontal
and occipital lobes in the control group and the patients. In the
control group, we found a slightly lower FDG uptake in the
frontal and temporal lobes compared with the occipital lobes (F/
O-R: mean 6 SDs 0.8860.06, range 0.75e1.0, 95% CI 0.85 to
0.90; T/O-R: mean 6 SD 0.8360.04, range 0.75e0.90, 95% CI
0.81 to 0.84). In our patients with NMDAR-ab encephalitis,
both F/O-R and T/O-R in one of two PETs performed in
moderate disease (mRS 3), and in all PETs performed during
severe disease (mRS 4e5), were abnormally elevated (upper limit
Table 1 18F-fluoro-2-deoxy-d-glucose positron emission
tomography (FDG-PET) characteristics in patients with
N-methyl-D-aspartate receptor antibody encephalitis
PET characteristics Number of patients Patient#
Abnormalities 6/6 1e6
Hypermetabolism
Unilateral temporal 4/6 1, 2, 5
Bilateral temporal 2/6 4, 6
Cerebellar 3/6 4, 5, 6
Frontolateral 3/6 2, 4, 6
Frontobasal 3/6 2, 3, 6
Hypometabolism
Bioccipital 3/6 4, 5, 6
Figure 1 Representative images of abnormal cerebral glucose metabolism in individual patients with N-methyl-D-aspartate receptor antibody
encephalitis detected by 18F-fluoro-2-deoxy-d-glucose positron emission tomography. Patients with mild or moderate clinical severity (patients #1
and #2; mRS#3) show temporomesial hyperintensities, whereas more widespread frontal and temporal hyperintensities and occipital hypointensities
in patients with severe disease (patients #4 and #6; mRS >3) are observed. Representative sections are shown (all images available in online
supplementary figure 1). Significant hyper- and hypometabolism is colour/gray-scale coded as depicted in the legend. mRS, modified Rankin Scale.
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deﬁned as mean + 2SDs of controls: F/O-R 1.0, T/O-R 0.91,
ﬁgure 3A,B). The F/O-R and T/O-R in PETs taken during active
disease (mRS >0) were signiﬁcantly higher compared with
controls (F/O-R: 1.0260.08, unpaired two-tailed t test, p¼0.001,
T/O-R: 1.0060.09, unpaired two-tailed t test, p<0.001). More-
over, the F/O-R and T/O-R in patients with NMDAR-ab
encephalitis both strongly correlated with disease severity
measurement as mRS (F/O-R: Spearman correlation coefﬁcient
¼0.818, p¼0.024; T/O-R, Spearman correlation coefﬁcient
¼0.873, p¼0.01).
Next, we asked whether the F/O-R and T/O-R returned to
normal values upon recovery. In both patients (patient #3,
initial mRS 3, patient #5, initial mRS 5), F/O-R as well as the T/
O-R were initially abnormal and decreased to normal values
within mean 62SDs of controls in the follow-up PET, when,
clinically, both were only mildly affected (mRS 1, ﬁgure 3C,D).
DISCUSSION
In this study, we analysed the brain glucose metabolism
detected by FDG-PET in a cohort of patients with NMDAR-ab
encephalitis. We found a pattern of abnormalities consisting of
a relative hypermetabolism in the frontal and temporal lobes,
and a relative hypometabolism in the occipital lobes in four of
ﬁve patients during active disease. Patient #2 underwent FDG-
PET imaging late after disease onset (30 weeks) and had
a mainly psychiatric manifestation of the disease. Both might be
the reasons for the circumscribed changes of cerebral glucose
metabolism in this case. The extent of the changes of cerebral
glucose metabolism was associated with clinical disability and
recovery of the disease. Indeed, the ratios of frontal-to-occipital,
and temporal-to-occipital FDG uptake, were reliable markers for
the active disease, returned to normal upon recovery and
correlated with disease severity. In addition, a restricted
temporomesial hypermetabolism was detected in a patient with
presymptomatic NMDAR-ab encephalitis.
Previous single-case reports have reported FDG-PET images in
NMDAR-ab encephalitis. In seven patients with ovarian tera-
toma and encephalitis, a combination suggesting NMDAR-ab
encephalitis although NMDAR-ab were not tested for, mainly
uni- or bilateral temporal, in some cases cerebellar hyperme-
tabolisms, and in one patient occipital hypometabolism had
Figure 2 Changes upon recovery and the common pattern of abnormal cerebral glucose metabolism in N-methyl-D-aspartate receptor antibodies
(NMDAR-ab) encephalitis. (A) Normalisation of 18F-fluoro-2-deoxy-d-glucose positron emission tomography brain metabolism in NMDAR-ab
encephalitis in two patients. Subtraction analysis for both patients (baseline vs follow-up; threshold at 2 SDs). Increase/decrease of metabolism upon
recovery according to legend. (B) Groupwise analysis of patients with NMDAR-ab encephalitis during active or presymptomatic disease (n¼5)
compared with controls (n¼24; false detection rate<0.05). Significant temporal, frontobasal, cerebellar and right-sided frontal hypermetabolism is
detected, as well as occipital and asymmetric parietal hypometabolism.
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been observed.16 17 In a severe case of NMDAR-ab encephalitis,
symmetric hypometabolism of the occipital lobes and cere-
bellum and asymmetric hypermetabolism of the frontal,
temporal and parietal lobes were detected.5 In less severe cases,
only right frontolateral hypermetabolism,7 or only occipital
hypometabolism, was described.8 These observations are in line
with our ﬁndings. However, some published cases differ from
this pattern. A case described striatal hypermetabolism in
addition to occipital hypometabolism,4 although the interpre-
tation of these ﬁndings is difﬁcult due to concurrent phenobar-
bital, midazolam and phenytoin medication. A study in which
FDG-PET was examined in three patients mentions areas of
hypermetabolism in frontotemporal, cerebellar and occipital
regions, although individual images and detailed clinical infor-
mation of these patients were not provided.9 Furthermore, in
two young girls (aged 3 and 7 years), predominantly unilateral
temporal cortical hypometabolism without any areas of hyper-
metabolism were reported.18 Since our cohort represents young
adults (mean 21 years), this might be due to different abnor-
malities of brain glucose metabolism in children and teenagers
with this disease. Similar to our observations, normalisation of
FDG-PET abnormalities after recovery has been observed previ-
ously in two cases (bifrontal hypermetabolism6; striatal hyper
and occipital hypometabolism4).
Abnormalities in brain FDG-PET have long been known to
occur in autoimmune encephalitis of various origins. In enceph-
alitis attributed to voltage-gated potassium channel complex
antibodies (now related to Lgi1 or Caspr2 antibodies), bilateral
temporomesial hypermetabolism and frontal and/or temporal
hypometabolism have been described.19e21 In paraneoplastic
limbic encephalitis with classical onconeural antibodies (anti-Hu),
usually only temporomesial hypermetabolism is observed.22 23 In
neuropsychiatric lupus erythematosus, as NMDAR-ab encepha-
litis, an immune-mediated disease frequently associated with
psychosis, often striatal hypermetabolism and sometimes wide-
spread frontoparietal hypometabolism were reported.24 25 In none
of these cases, frontal hypermetabolism in combination with
occipital hypometabolism, was identiﬁed. Hence, the pattern of
abnormal brain glucose metabolism detected in NMDAR-ab
encephalitis might be characteristic of this syndrome.
The pathophysiological basis of this metabolic signature of
NMDAR-ab encephalitis is not known. However, the few
available autopsy studies26 27 in NMDAR-ab encephalitis do not
show extensive neuronal loss, complement deposition, or
cellular inﬁltration, arguing against cellular or complement-
mediated cytotoxicity as has been observed in other types of
autoimmune encephalitis.28 Rather, meningeal plasma cells are
observed.29 Therefore, it is tempting to speculate, that the
detected cerebral glucose metabolism is caused by a potentially
reversible disruption of synaptic NMDAR function by NMDAR-
abs. In vitro, this has been shown by whole-cell patch clamp
recordings in cultured rat hippocampal neurons as patients’
antibodies speciﬁcally decreased synaptic NMDAR-mediated
miniature excitatory postsynaptic currents without affecting a-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor-mediated currents.1 26 Glutamatergic signalling via
NMDAR in humans is observed widely in limbic, frontal,
temporal and cerebellar areas.30 NMDAR antagonism has a 10-
fold greater effect on GABAergic (g-Aminobutyric acid (GABA))
than on glutamatergic cells. The downregulation of the
GABAergic tone,31 therefore, leads to an overall state of disin-
hibition with increased excitatory glutamate effects via non-
NMDA glutamate receptors, especially in the frontal lobes.32
Further evidence for this hypothesis stems from the fact, that
the anaesthetic, ketamine, is an NMDAR antagonist33 which
induces dissociative anaesthesia, vivid hallucinations and frank
psychosis in humans, features in part resembling symptoms of
patients with NMDAR-ab encephalitis.34 Of note, if ketamine is
applied to healthy human subjects, the frontal-to-occipital
gradient of glucose metabolism detected by FDG-PET is
increased,35 36 a pattern that resembles the observed changes in
our patients with NMDAR-ab encephalitis. In animals, similar
effects were demonstrated upon treatment with ketamine and
another NMDA-antagonist, phencyclidine.37 38 Taken together,
we hypothesise that the pattern of abnormal brain glucose
metabolism detected in NMDAR-ab encephalitis might be
a direct result from disrupted NMDAR signalling.
This study has several limitations. First, the analysis was
performed retrospectively, and we extracted the data of regional
FDG uptake for statistical analysis from whole-body PET
imaging. This resulted in reduced spatial resolution of the brain
PET images compared with dedicated brain PET imaging.
Second, FDG-PET was not performed in all patients diagnosed
with NMDAR-ab encephalitis in our clinics, which results in
Figure 3 An increased frontal- and
temporal-to-occipital 18F-fluoro-2-
deoxy-d-glucose (FDG) uptake is
associated with disease severity in
N-methyl-D-aspartate receptor
antibodies encephalitis. Ratio of mean
frontal to mean occipital (A), and of
mean temporal to mean occipital FDG
uptake (B), in controls and patients by
disease severity modified Rankin Scale
(mRS). Both ratios are significantly
elevated in active disease (mRS >0)
compared with controls (unpaired
two-tailed t test, p<0.001). (C/D)
Normalisation of fronto-occipital and
temporo-occipital ratio upon clinical
recovery in two individual patients.
The upper limit defined as mean 6
2SDs of the control group is depicted
as dotted line.
J Neurol Neurosurg Psychiatry 2012;83:681e686. doi:10.1136/jnnp-2011-301969 685
Neuro-inflammation
group.bmj.com on September 5, 2017 - Published by http://jnnp.bmj.com/Downloaded from 
a small sample size and a potential selection bias. Third, follow-
up FDG-PET investigations were only available from a minority
of patients.
In conclusion, the data presented provide a detailed descrip-
tion of changes of brain glucose metabolism in patients with
NMDAR-ab encephalitis, consisting of an increased fronto-
temporal-to-occipital gradient, which correlates with disease
severity. As some aspects of the pattern resemble changes in
brain glucose metabolism in drug-induced psychosis, it is
tempting to speculate that the neuropsychiatric symptoms
characteristic for NMDAR-ab encephalitis are linked to changes
of brain metabolism described herein. Larger prospective studies
are needed to further delineate the pattern of NMDAR-ab
encephalitis and reproduce these observations.
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